OTCM
CKDXF
Market cap4mUSD
, Last price
USD
Name
Opthea Ltd
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
36.25%
Rev. 5Y
-29.73%
Div Yld LY
—
Div Yld TTM
—
Revenues
25k
-79.95%
Net income
-164m
L-25.63%
CFO
-159m
L-1.12%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
Key people
Founder, Chief Innovation Office · since 2024
Dayong Li
Senior Vice President - Biometrics · since 2024
Anthony Bonifazio
Vice President - Market Access · since 2024
Mark O'neill
Vice President - Chemistry, Manufacturing and Controls · since 2022
Anand Sundaram
Vice President - Marketing · since 2024
Jennifer Watts
Vice President - Global Clinical Operations · since 2024
Kevin Bitter
Vice President - Strategy and Corporate Development · since 2024
Mike Campbell
Chief Commercial Officer · since 2024
Parisa Zamiri
Chief Medical Officer · since 2024
Karen Adams
Vice President - Finance, Company Secretary · since 2021
Hamish George
Chief Financial Officer, Joint Company Secretary · since 2025
Stephanie Vipond
Joint Company Secretary · since 2025
Katherine Connell
Non-Executive Director · since 2024
Anshul Thakral
Non-Executive Director · since 2023
Non-Executive Independent Chairman of the Board · since 2020
Lawrence Gozlan
Non-Executive Independent Director · since 2020
Non-Executive Independent Director · since 2021
Susan Orr
Non-Executive Independent Director · since 2022
Quinton Oswald
Non-Executive Independent Director · since 2022
Legal address
'Prime Company Compliance' Level 9
505 Little Collins Street
MELBOURNE, VIC 3000
AU
505 Little Collins Street
MELBOURNE, VIC 3000
AU
Headquarters
Level 9
505 Little Collins Street
MELBOURNE, VIC 3000
AU
505 Little Collins Street
MELBOURNE, VIC 3000
AU
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||